Voloridge Investment Management
SAGE

Voloridge Investment Management’s Sage Therapeutics SAGE Stock Holding History

Voloridge Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-87,981
Closed -$478K – 1346
2024
Q4 		$478K Sell
87,981
-234,954
-73% -$1.44M ﹤0.01% 1103
2024
Q3 		$2.33M Sell
322,935
-106,902
-25% -$979K 0.01% 921
2024
Q2 		$4.67M Sell
429,837
-122,804
-22% -$1.57M 0.02% 764
2024
Q1 		$10.4M Buy
552,641
+159,942
+41% +$3.69M 0.04% 483
2023
Q4 		$8.51M Buy
392,699
+321,731
+453% +$6.38M 0.03% 507
2023
Q3 		$1.46M Buy
+70,968
New +$2.05M 0.01% 1015
2022
Q3 		– Sell
-132,101
Closed -$4.27M – 1596
2022
Q2 		$4.27M Buy
132,101
+87,661
+197% +$2.94M 0.02% 735
2022
Q1 		$1.47M Sell
44,440
-89,805
-67% -$3.38M 0.01% 1041
2021
Q4 		$5.71M Sell
134,245
-105,962
-44% -$4.44M 0.03% 674
2021
Q3 		$10.6M Buy
240,207
+93,661
+64% +$4.3M 0.07% 408
2021
Q2 		$8.32M Sell
146,546
-20,513
-12% -$1.45M 0.06% 468
2021
Q1 		$12.5M Sell
167,059
-7,640
-4% -$626K 0.09% 291
2020
Q4 		$15.1M Buy
174,699
+9,452
+6% +$697K 0.13% 197
2020
Q3 		$10.1M Sell
165,247
-182,106
-52% -$9.23M 0.08% 261
2020
Q2 		$14.4M Buy
347,353
+143,641
+71% +$5.21M 0.17% 129
2020
Q1 		$5.85M Buy
203,712
+187,161
+1,131% +$10.8M 0.17% 134
2019
Q4 		$1.2M Sell
16,551
-973
-6% -$120K 0.02% 600
2019
Q3 		$2.46M Buy
+17,524
New +$2.93M 0.04% 399
2018
Q1 		– Sell
-53,908
Closed -$8.88M – 633
2017
Q4 		$8.88M Buy
+53,908
New +$5.23M 0.19% 129
2017
Q3 		– Sell
-73,953
Closed -$5.89M – 516
2017
Q2 		$5.89M Sell
73,953
-9,400
-11% -$680K 0.15% 153
2017
Q1 		$5.92M Buy
83,353
+33,087
+66% +$1.94M 0.14% 179
2016
Q4 		$2.57M Buy
+50,266
New +$2.37M 0.06% 362

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Voloridge Investment Management's SAGE Position: Q1 2025 in Review

Voloridge Investment Management sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 87,981 shares — an estimated $478K sold.

Voloridge Investment Management first reported a position in SAGE in Q4 2016 and held it in 22 quarters. The position peaked at $15.1M in Q4 2020. 197 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Voloridge Investment Management reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 87,981 Sage Therapeutics shares in Q1 2025, an estimated $478K.
  • Voloridge Investment Management first reported a position in Sage Therapeutics in Q4 2016 and held it in 22 quarters.
  • Voloridge Investment Management's Sage Therapeutics position peaked at $15.1M in Q4 2020.
  • 197 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Voloridge Investment Management's 13F filing for Q1 2025, filed 15 May 2025.